|
Thyroid Neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The mixed expression of BRAF under varying levels of differentiation may explain, in part, the contradictory studies regarding the impact of BRAF mutations on patient prognosis and also indicates a complex genomic signature for dedifferentiated thyroid cancer.
|
31229486 |
2019 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.
|
14602780 |
2003 |
|
Thyroid Neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We conclude that both mutational events as well as over-expression of BRAF gene is highly implicated in pathogenesis of thyroid cancer and the BRAF protein over-expression is independent of the BRAF mutational status of thyroid cancer patients.
|
24442520 |
2014 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.
|
21351275 |
2010 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas.
|
15145515 |
2004 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Patients with RAIR, BRAF mutant thyroid cancer.
|
30256977 |
2019 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
These data unmask an epigenetically controlled FGFR2 signal that imposes precisely on the intragenically modified BRAF/MAPK pathway to modulate thyroid cancer behavior.
|
17545628 |
2007 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF provides signals crucial for proliferation of thyroid carcinoma cells spontaneously harboring the (V600E)BRAF mutation and, therefore, BRAF suppression might have therapeutic potential in (V600E)BRAF-positive thyroid cancer.
|
16533790 |
2006 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to determine whether combined detection of BRAF(V600E) mutation and methylation markers on FNABs could improve the diagnostic accuracy of thyroid cancer.
|
24588959 |
2014 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
We for the first time demonstrated potent inhibitory effects of a MEK inhibitor, CI-1040, on thyroid cancer cells, some of which, particularly cell proliferation and tumor growth, seemed to be BRAF mutation or RAS mutation selective.
|
17911174 |
2007 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V600E) mutation analysis is superior to RAS point mutations and evaluation of RET/PTC rearrangements in the diagnosis of thyroid cancer, even in indeterminate lesions.
|
25333496 |
2015 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Triple combination of PLX4032, SAHA, and TSH is a specific robust regimen to restore RAI avidity in RAI-refractory BRAF V600E-positive thyroid cancer, which warrants clinical trials to confirm.
|
26751190 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations.
|
24248188 |
2014 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The identification of BRAF mutations in thyroid cancer has prognostic and therapeutic implications.
|
29579361 |
2018 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We examined BRAF(T1796A) in 21 patients with thyroid tumors using leftover cells in the needle at the preoperative FNAB.
|
15671769 |
2004 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The objectives of the study were: 1) to determine the prevalence of TERT promoter mutations C228T and C250T in different thyroid cancer histological types and cell lines; and 2) to establish the possible association of TERT mutations with mutations of BRAF, RAS, or RET/PTC.
|
23833040 |
2013 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This study investigates the expression of CYP24A1 and the effect of BRAF(V600E) on its expression in thyroid cancer.
|
24382015 |
2014 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
While mutation of the BRAF gene, corresponding to the constitutively active BRAF(V600E) protein, has been associated with worse clinical outcomes in thyroid cancer, the reasons underlying this observation are presently unknown.
|
24955518 |
2014 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Suppression of BRAF pathway in thyroid cancer cell lines (8505C, TPC1 and C643) was achieved using RNA interference (RNAi) for BRAF and the kinase inhibitor, sorafenib.
|
19878585 |
2009 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Common somatic mutations in BRAF, rearranged in transformation/papillary thyroid carcinomas (RET/PTC) and neurotrophin receptor-tyrosine kinase (NTRK) also do not account for the gender disparity in thyroid cancer.
|
21142662 |
2010 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The BRAF(V600E) mutation can be detected peripherally in the serum of patients with thyroid cancer.
|
23161556 |
2013 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Knockdown of WIPF1 robustly inhibited anchorage-independent colony formation, migration, and invasion of thyroid cancer cells and suppressed xenograft thyroid cancer tumor growth and vascular invasion, mimicking the effects of BRAF knockdown.
|
27863429 |
2017 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Small molecule inhibitors that selectively target B-Raf(V600E) may provide clinical benefit for patients with thyroid cancer.
|
17363500 |
2007 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Thus, TERT with promoter mutations represents a prominent new oncogene in thyroid cancer and the mutations are promising new diagnostic and prognostic genetic markers for thyroid cancer, which, in combination with BRAF V600E mutation or other genetic markers (e.g.
|
26733501 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Additionally, somatic p.V600E BRAF mutations were also detected in the thyroid tumors of two members of the family carrying the p.A248G variant.
|
25381600 |
2015 |